Establishment of a CCR5-Expressing T-Lymphoblastoid Cell Line Highly Susceptible to R5 HIV Type 1
- 1 July 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 16 (10) , 935-941
- https://doi.org/10.1089/08892220050058344
Abstract
The β-chemokine receptor CCR5 is considered to be an attractive target for inhibition of CCR5-using (R5 or macrophage-tropic) HIV-1. However, R5 HIV-1 cannot replicate in CD4+ T cell or monocyte lines because of the lack of CCR5 expression on their surface, which apparently hampers discovery and development of effective CCR5 antagonists against HIV-1 replication. In this study, we have established the CCR5-expressing T cell line MOLT-4/CCR5, highly permissive to the replication of R5 HIV-1. The cells express a considerable amount of CCR5 on their surface. When the cells were infected with the R5 HIV-1 strains Ba-L and JR-FL, the virus-induced cytopathic effect (syncytium formation) was observed, and the cells produced large amounts of HIV-1 p24 antigen in the culture supernatants. The analyses of progeny viruses for their coreceptor use and gp120 V3 nucleotide sequence revealed that they were R5 HIV-1. The parental cell line MOLT-4 was much less susceptible to Ba-L and totally insusceptible to JR-FL. Furthermore, MOLT-4/CCR5 cells could support the replication of an R5 clinical isolate, but MOLT-4 cells could not. When TAK-779, a novel smallmolecule nonpeptide CCR5 antagonist, was examined for its inhibitory effect on R5 HIV-1 replication in MOLT-4/CCR5 cells, the compound displayed potent antiviral activity, as demonstrated in peripheral blood mononuclear cells. These results indicate that the established cell line will be an extremely useful tool for experiments with R5 HIV-1.Keywords
This publication has 24 references indexed in Scilit:
- A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activityProceedings of the National Academy of Sciences, 1999
- CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and DiseaseAnnual Review of Immunology, 1999
- In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppressionNature Medicine, 1997
- Co-receptors for HIV-1 entryCurrent Opinion in Immunology, 1997
- HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptorThe EMBO Journal, 1997
- The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infectionNature Medicine, 1996
- Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor SpecificityCell, 1996
- Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor geneNature, 1996
- Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 InfectionCell, 1996
- Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent AntagonistJournal of Biological Chemistry, 1996